190 related articles for article (PubMed ID: 30389727)
21. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
Lacson E; Hakim RM
Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
[No Abstract] [Full Text] [Related]
22. How dialysis is paid for: what the dialysis medical director should know, and why.
Deoreo PB
Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
[TBL] [Abstract][Full Text] [Related]
23. The 2011 ESRD prospective payment system: an uncontrolled experiment.
Winkelmayer WC; Chertow GM
Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
[No Abstract] [Full Text] [Related]
24. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
Bhat P; Bhat JG
Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
[No Abstract] [Full Text] [Related]
25. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
Nissenson AR; Mayne TJ; Krishnan M
Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
[No Abstract] [Full Text] [Related]
26. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2002.
Johnson P
Issue Brief Health Policy Track Serv; 2002 Dec; ():1-15. PubMed ID: 12877157
[TBL] [Abstract][Full Text] [Related]
27. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
Johnson DS; Meyer KB; Johnson HK
Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
[No Abstract] [Full Text] [Related]
28. Who should be paying for vitamin D analogues--Medicare or the patients?
Hall G
Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205
[No Abstract] [Full Text] [Related]
29. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
30. An unfortunate tradition.
Swenson L
Minn Med; 2012 Jan; 95(1):34. PubMed ID: 22355910
[No Abstract] [Full Text] [Related]
31. Overview 2012. A year of dialysis industry alignment and government enforcement.
Riley JB; Greis JS
Nephrol News Issues; 2013 Mar; 27(3):37-8. PubMed ID: 23581175
[TBL] [Abstract][Full Text] [Related]
32. The American health care system. The End Stage Renal Disease Program.
Iglehart JK
N Engl J Med; 1993 Feb; 328(5):366-71. PubMed ID: 8419833
[No Abstract] [Full Text] [Related]
33. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2017 Nov; 82(210):50738-97. PubMed ID: 29091373
[TBL] [Abstract][Full Text] [Related]
34. Renal Dialysis and its Financing.
Borelli M; Paul DP; Skiba M
Hosp Top; 2016; 94(2):33-8. PubMed ID: 27315562
[TBL] [Abstract][Full Text] [Related]
35. A glimmer of hope for rural dialysis units.
Beyer L
Nephrol News Issues; 2011 Apr; 25(4):29. PubMed ID: 21542512
[No Abstract] [Full Text] [Related]
36. The Medicare end-stage renal disease program. A report from the Institute of Medicine.
Levinsky NG; Rettig RA
N Engl J Med; 1991 Apr; 324(16):1143-8. PubMed ID: 2008193
[No Abstract] [Full Text] [Related]
37. The drug add-on component--have all provider types seen budget neutrality?
Mentz K
Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646
[No Abstract] [Full Text] [Related]
38. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
39. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
[TBL] [Abstract][Full Text] [Related]
40. Policy and research in end-stage renal disease.
Jones KR
Image J Nurs Sch; 1987; 19(3):126-9. PubMed ID: 3117675
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
